

CERTIFICATE OF ANALYSIS

* FOR QUALITY ASSURANCE PURPOSES. NOT A MAINE COMPLIANCE CERTIFICATE.

TANGERINE HAZE (FLOWER) // PRODUCED: MAR 16, 2022

CLIENT: TREETOP CROPS OF MAINE, LLC. // BATCH: PASS



MATRIX: FLOWER
SAMPLE ID: NAL-220311-016
COLLECTED ON: MAR 11, 2022
RECEIVED ON: MAR 11, 2022
SAMPLE SIZE: 1 G
SAMPLED BY: KAYLIN KEITH
RECEIVED BY: KAYLIN KEITH

CANNABINOID OVERVIEW

THCA:	24.0 %
CBGA:	2.33 %
TOTAL CANNABINOIDS:	26.3 %

CULTIVATOR INFO

CULTIVATOR
MARK MANCINI
91 AUBURN ST. #10210
PORTLAND, ME 04103

LICENSE
CGR29831
MEDICINAL - CAREGIVER

BATCH RESULT: PASS

POTENCY TESTED

CAN. 1: POTENCY & CANNABINOID PROFILE BY HPLC-UV PREPARATION: MAR 15, 2022 // ANALYSIS: MAR 15, 2022

ANALYTE	LIMIT	AMT	AMT	LOD/LOQ (%)	PASS/FAIL
CBC		ND	ND	0.206/1.03	N/A
CBCA		ND	ND	0.206/1.03	N/A
CBD		ND	ND	0.206/1.03	N/A
CBDA		ND	ND	0.206/1.03	N/A
CBDV		ND	ND	0.206/1.03	N/A
CBDVA		ND	ND	0.206/1.03	N/A
CBG		ND	ND	0.206/1.03	N/A
CBGA	2.33 %	23.3 mg/g		0.206/1.03	N/A
CBL		ND	ND	0.206/1.03	N/A
CBLA		ND	ND	0.206/1.03	N/A
CBN		ND	ND	0.206/1.03	N/A

ANALYTE	LIMIT	AMT	AMT	LOD/LOQ (%)	PASS/FAIL
CBNA		ND	ND	0.206/1.03	N/A
Δ ⁸ -THC		ND	ND	0.206/1.03	N/A
Δ ⁹ -THC	< LOQ	< LOQ		0.206/1.03	N/A
Δ ¹⁰ -THC		ND	ND	0.206/1.03	N/A
EXO-THC		ND	ND	0.206/1.03	N/A
THCA	24.0 %	240 mg/g		0.206/1.03	N/A
THCV		ND	ND	0.206/1.03	N/A
THCVA		ND	ND	0.206/1.03	N/A
TOTAL THC **	21.0 %	210 mg/g			N/A
TOTAL CBD **		ND	ND		N/A

** TOTAL CBD = (CBDA X 0.877) + CBD

** TOTAL THC = (THCA X 0.877) + THC

Reported on an as received basis

1000 µg/g = 1 mg/g



RESULTS CERTIFIED BY:
BARRY CHAFFIN
COO, NOVA ANALYTIC LABS
MAR 16, 2022

RESULTS CERTIFIED BY:
GREG NEWLAND
CSO, NOVA ANALYTIC LABS
MAR 16, 2022

RESULTS CERTIFIED BY:
CHRIS ALTOMARE
CEO, NOVA ANALYTIC LABS
MAR 16, 2022

* FOR QUALITY ASSURANCE PURPOSES. NOT A MAINE COMPLIANCE CERTIFICATE.

ALL TESTS WERE PERFORMED IN ACCORDANCE WITH THE RULES AND REGULATIONS SET FORTH IN THE MAINE ADULT USE PROGRAM. LABORATORY SAMPLING PROTOCOLS ARE GOVERNED BY THE OMP'S SAMPLING GUIDANCE DOCUMENTS. ALL INFORMATION PROVIDED BY THE CLIENT, INCLUDING SELF SAMPLING, MUST BE ACCURATE AND ADHERE TO THE SAME RULES AND REGULATIONS. HOWEVER, CLIENT PROVIDED INFORMATION, INCLUDING SAMPLING, IS ULTIMATELY THE RESPONSIBILITY OF THE PROVIDING LICENSEE, REGISTERED CAREGIVER, PATIENT OR THE LIKE AND FAILURE TO FOLLOW SAID PROTOCOLS COULD LEAD TO ERRONEOUS TEST RESULTS. NOTE: NOT ALL POTENTIAL AND/OR EXISTING HAZARDS WERE ANALYZED.

END OF REPORT